✦ LIBER ✦

Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial)

✍ Scribed by Costa, S.D.; du Bois, A.; Lueck, H.J.; Meier, W.; Moebus, V.; Bauknecht, T.; Richter, B.; Schroeder, W.; Warms, S.; Olbricht, S.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of patients with advanced ovar

✍ W. Schröder; A. du Bois; W. Kuhn; H.J. Lück; V. Möbus; W. Meier; U. Nitz; S. Olb 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Impact of age on outcome in patients wit

✍ Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Topotecan versus treosulfan, an alkylati

✍ Werner Meier; Andreas du Bois; Alexander Reuss; Walther Kuhn; Sigrid Olbricht; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 545 KB

36 Paclitaxel/Carboplatin(TC) vs Paclita

✍ E. Pujade-Lauraine; J. Pfisterer; A. Lortholary; R. Kimmig; B. Weber; A. du Bois 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Docetaxel and carboplatin as first-line

✍ J Pfisterer; A du Bois; U Wagner; J Quaas; J.U Blohmer; D Wallwiener; F Hilpert 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 123 KB

A randomized phase III trial of IV carbo

✍ Robert S. Mannel; Mark F. Brady; Elise C. Kohn; Parviz Hanjani; Masamichi Hiura; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 371 KB